Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 11;15(20):4940.
doi: 10.3390/cancers15204940.

Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review

Fabien Moinard-Butot  1 , Simon Nannini  1 , Cathie Fischbach  1 , Safa Abdallahoui  1 , Martin Demarchi  1 , Thierry Petit  1 , Laura Bender  1 , Roland Schott  1
Affiliations
Review

Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review

Fabien Moinard-Butot et al. Cancers (Basel). .

Abstract

Lung cancers with ALK rearrangement represent less than 5% of all lung cancers. ALK inhibitors are currently used to treat first-line metastatic non-small cell lung cancer with ALK rearrangement. Compared to chemotherapy, ALK inhibitors have improved progression-free survival, overall survival, and quality of life for patients. The results of several phase 3 studies with a follow-up of over 6 years suggest that the life expectancy of these patients treated with targeted therapies is significantly higher than 5 years and could approach 10 years. Nevertheless, these treatments induce haematological toxicities, including neutropenia. Few data are available on neutropenia induced by ALK inhibitors and on the pathophysiological mechanism and therapeutic adaptations necessary to continue the treatment. Given the high efficacy of these treatments, managing side effects to avoid treatment interruptions is essential. Here, we have reviewed the data from published clinical studies and case reports to provide an overview of neutropenia induced by ALK inhibitors.

Keywords: ALK inhibitor; NSCLC; haematological toxicities; neutropenia.

PubMed Disclaimer

Conflict of interest statement

R.S. declared Roche for an advisory role, Pfizer, and Takeda for travel and accommodation.

Figures

Figure 1
Figure 1
Study selection.
See this image and copyright information in PMC

References

    1. Rolfo C., Caglevic C., Santarpia M., Araujo A., Giovannetti E., Gallardo C.D., Pauwels P., Mahave M. Immunotherapy in NSCLC: A promising and revolutionary weapon. Adv. Exp. Med. Biol. 2017;995:97–125. doi: 10.1007/978-3-319-53156-4_5. - DOI - PubMed
    1. Devarakonda S., Morgensztern D., Govindan R. Genomic alterations in lung adenocarcinoma. Lancet Oncol. 2015;16:e342–e351. doi: 10.1016/S1470-2045(15)00077-7. - DOI - PubMed
    1. Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K.G., Shapiro D.N., Saltman D.L., Look A.T. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263:1281–1284. doi: 10.1126/science.8122112. - DOI - PubMed
    1. Novello S., Mazières J., Oh I.-J., de Castro J., Migliorino M., Helland A., Dziadziuszko R., Griesinger F., Kotb A., Zeaiter A., et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: Results from the phase III ALUR study. Ann. Oncol. 2018;29:1409–1416. doi: 10.1093/annonc/mdy121. - DOI - PMC - PubMed
    1. Solomon B.J., Kim D.-W., Wu Y.-L., Nakagawa K., Mekhail T., Felip E., Cappuzzo F., Paolini J., Usari T., Tang Y., et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non–small-cell lung cancer. J. Clin. Oncol. 2018;36:2251–2258. doi: 10.1200/JCO.2017.77.4794. - DOI - PubMed

LinkOut - more resources